Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

618
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
618
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

875
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
875
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

672
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
672
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

300
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
300

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Autoimmune encephalitis associated with autoimmune blistering diseases: A case series and retrospective review.

JAAD case reports·2023
Same author

Novel method to quantify phenotypic markers of HIV-associated neurocognitive disorder in a murine SCID model.

Journal of neurovirology·2020
Same author

HIV X4 Variants Increase Arachidonate 5-Lipoxygenase in the Pulmonary Microenvironment and are associated with Pulmonary Arterial Hypertension.

Scientific reports·2020
Same author

CNS inflammatory demyelinating disorders: MS, NMOSD and MOG antibody associated disease.

Journal of investigative medicine : the official publication of the American Federation for Clinical Research·2019
Same author

Baricitinib reverses HIV-associated neurocognitive disorders in a SCID mouse model and reservoir seeding in vitro.

Journal of neuroinflammation·2019
Same author

Linked CSF reduction of phosphorylated tau and IL-8 in HIV associated neurocognitive disorder.

Scientific reports·2019

Related Experiment Video

Updated: Mar 8, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.9K

Update on disease-modifying therapies for multiple sclerosis.

Diana L Vargas1, William R Tyor1

  • 1Department of Neurology, Emory University School of Medicine, Neurology Service, Atlanta VA Medical Center, Decatur, Georgia, USA.

Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research
|January 29, 2017
PubMed
Summary
This summary is machine-generated.

Multiple sclerosis (MS) is a CNS autoimmune disease impacting young adults. Disease-modifying therapies (DMTs) target inflammation to reduce relapses, new lesions, and disability progression.

Keywords:
Demyelinating DiseasesDisease ManagementImmunosuppressive Agents

More Related Videos

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.1K
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

4.8K

Related Experiment Videos

Last Updated: Mar 8, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.9K
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.1K
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

4.8K

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system (CNS), characterized by inflammation, demyelination, and axonal loss.
  • It is a leading cause of disability in young adults, predominantly affecting women.
  • MS treatment has evolved significantly over the past 60 years, focusing on managing the inflammatory response.

Purpose of the Study:

  • To review the landscape of disease-modifying therapies (DMTs) for multiple sclerosis.
  • To discuss the mechanisms, efficacy, and safety profiles of available and emerging MS treatments.
  • To emphasize the importance of timely and appropriate treatment initiation and adjustment in MS management.

Main Methods:

  • Review of existing literature on multiple sclerosis pathogenesis and treatment.
  • Discussion of pharmacological mechanisms of action for various DMTs.
  • Analysis of clinical outcomes, including relapse rates, lesion formation, and disability progression.

Main Results:

  • Several DMTs are available, targeting MS inflammation to reduce relapses and slow disability.
  • Early treatments like interferon-β and glatiramer acetate modulate the immune response.
  • Newer oral agents (fingolimod, dimethyl fumarate, teriflunomide) and potent injectables (natalizumab, alemtuzumab) offer improved efficacy but require careful risk-benefit assessment.
  • Ocrelizumab, a B-cell targeting monoclonal antibody, shows high efficacy.

Conclusions:

  • Disease-modifying therapies have transformed MS management, making it a treatable condition.
  • Prompt diagnosis and initiation of appropriate DMTs are crucial for optimal outcomes.
  • Ongoing monitoring for disease activity, disability progression, and treatment-related concerns is essential for effective long-term MS care.